An observational study in Stroke and Osteoporosis, sponsored by Ankara Etlik City Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 55 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Ankara Etlik City Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 487 studies in Stroke with a site in Turkey — 96 open to participants now, 109 under way, 3 of them phase 3. Stroke · Turkey.
Among the 487 studies in Stroke with a site in Turkey, this one is the 49th largest by planned enrollment of the 164 observational ones that give a count, is one of 71 that started in 2025, is one of 164 observational ones, reaches primary completion later than 69 of the 108 other live ones, and was the 372nd registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →96 of the 487 studies in Stroke with a site in Turkey are open now. Recruiting first, the newest first:
Izmir City Hospital · Sites in Turkey
Ages 18–90
Izmir City Hospital · Sites in Turkey
Ages 18–90
Istanbul University - Cerrahpasa · Sites in Turkey
Ages 18–75
Bitlis Eren University · Sites in Turkey
Ages 18–75
Istinye University · Sites in Turkey
Ages 40–70
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 55 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
487 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 71 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 84 is below the median of 150 across 1,971 observational studies indexed under Stroke.
Median enrollment 40 across the 323 interventional studies, 63 across the 164 observational. Of the 339 that completed or were terminated, 22 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 487 have an industry lead sponsor. The 10 most frequent:
Ankara Etlik City Hospital is the lead sponsor of 180 studies on the registry; 77 are open to participants now.
Ankara Etlik City Hospital has 9 studies filed under Stroke — fewer than ten, so there is no comparison to draw.
36 of the studies in Stroke with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07551141Bitlis Eren UniversityEffects of Plantar Vibration on Gait and Balance in Stroke | 2026-11 |
| NCT07550270Gaziler Physical Medicine and Rehabilitation Education and Research HospitalBody Weight-Supported and Virtual Reality Gait Training in Stroke Patients | 2026-11 |
| NCT07948187Nour ABDULRAHIM ALMNLAMirror Therapy With Olfactory-Motor Priming for Arm Recovery After Stroke | 2026-11-22 |
| NCT06166862Karamanoğlu Mehmetbey UniversityAction Observation and Motor Imagery Therapy in Stroke | 2026-12 |
| NCT07822854Nermin KARTVagal Stimulation in Individuals With Stroke | 2026-12-01 |
Add all 36 to your calendar (.ics) → With an account.
Among the 487 studies in Stroke with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to evaluate the effects of stroke and associated clinical, functional, nutritional, and muscular factors, including handgrip strength, on bone mineral density and osteoporosis by comparing patients with subacute stroke, patients with chronic stroke, and non-stroke controls. By identifying factors associated with reduced bone mineral density and osteoporosis across these groups, the study is expected to contribute to the identification of high-risk patients and provide a basis for future research aimed at improving screening and treatment strategies. No significant risks are anticipated from participation in this study.
The primary outcomes of this study will be bone mineral density (BMD), expressed in g/cm², and T-scores measured by dual-energy X-ray absorptiometry (DXA) at the lumbar spine and hip. Additionally, the prevalence of osteoporosis and low bone mass will be evaluated using appropriate diagnostic criteria.
Secondary outcomes will include handgrip strength measured using a hand dynamometer, anterior thigh and anterior arm muscle thickness assessed by ultrasonography (mm), motor recovery evaluated using the Brunnstrom Recovery Stages, spasticity assessed using the Modified Ashworth Scale (MAS), functional independence measured by the Modified Barthel Index (MBI), and fall-related self-efficacy evaluated using the Modified Falls Efficacy Scale (MFES). Biochemical parameters, including serum vitamin D (ng/mL), albumin (g/dL), and prealbumin (mg/dL), will also be recorded. These outcomes will be used to investigate potential factors associated with reduced BMD and osteoporosis.
The criteria were revised on the registry on Nov 2, 2026. See what changed
Fifty-six stroke patients receiving inpatient treatment will be evaluated. In addition, patients who have visited the outpatient clinic and have already undergone BMD scanning for osteoporosis screening, with similar age and comorbidities, will be screened from the system, and 28 non-stroke patients who agree to participate will be randomly included in the study.
Inclusion Criteria:
Exclusion Criteria:
No history of ischemic or hemorrhagic stroke.
Being between 55 and 85 years of age.
Ability to undergo the required clinical assessments and DXA measurements.
Exclusion Criteria for Non-Stroke Controls
Presence of a neurological condition causing significant physical functional impairment.
Presence of a psychiatric condition that may interfere with participation in the study or completion of assessments.
History of any cerebrovascular event, including .
Having undergone a BMD scan within the last year.
Having received osteoporosis treatment.
History of fragility fracture.
History of hip fracture or presence of a hip prosthesis.
Presence of any medical or musculoskeletal condition causing significant physical functional impairment or mobility limitations (e.g., amputation or severe fracture).
Presence of any disease or medication use associated with secondary osteoporosis.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients for whom 1 week to 6 months have passed since the incident
Diagnostic Test: Bone Mineral Density
Patients for whom more than one year has passed since the date of the incident
Diagnostic Test: Bone Mineral Density
Diagnostic Test: Bone Mineral Density
Patients who have had a stroke and are at risk of fracture, and for whom routine assessment requires Bone Mineral Density (BMD) testing, will be included in the study. In addition, patients who have already undergone BMD testing for osteoporosis screening and who present to the outpatient clinic, with similar age and comorbidities, will be screened from the system, and 28 non-stroke patients who agree to participate will be included in the study.
Bone Mineral Density
Bone mineral density (BMD) will be assessed in patients with stroke using dual-energy X-ray absorptiometry (DXA). Measurements will be performed at the lumbar spine and hip. BMD values will be recorded in grams per square centimeter (g/cm²), and the corresponding T-scores will also be documented for each anatomical site.
Time frame: First day of hospitalization for stroke patient, during an outpatient visit for non stroke control
Brunnstrom
Brunnstrom Recovery Stages will be used to assess motor recovery in patients with stroke. This assessment classifies motor recovery into six stages, ranging from flaccidity (Stage I) to near-normal voluntary movement and coordination (Stage VI). The upper extremity, hand, and lower extremity will be evaluated separately, with higher stages indicating better motor recovery.
Time frame: First day of hospitalization for stroke patient, during an outpatient visit for non stroke control
Modified Barthel Index
The Modified Barthel Index (MBI) will be used to assess functional independence in activities of daily living in patients with stroke. The index evaluates 10 activities, including feeding, bathing, dressing, toileting, transfers, and mobility. Total scores range from 0 to 100, with higher scores indicating greater functional independence.
Time frame: First day of hospitalization for stroke patient, during an outpatient visit for non stroke control
Modified Ashworth Scale
The Modified Ashworth Scale (MAS) will be used to assess muscle spasticity in patients with stroke. The scale evaluates resistance to passive movement using six grades (0, 1, 1+, 2, 3, and 4), with higher grades indicating greater muscle tone and resistance to passive movement.
Time frame: First day of hospitalization for stroke patient, during an outpatient visit for non stroke control
Modified Falls Efficacy Scale (MFES)
The Modified Falls Efficacy Scale (MFES) will be used to assess fall-related self-efficacy in patients with stroke. The scale consists of 14 items evaluating confidence in performing daily activities without falling. Each item is scored from 0 to 10, with higher scores indicating greater confidence and lower fear of falling.
Time frame: First day of hospitalization for stroke patient, during an outpatient visit for non stroke control
Vitamin D
Vitamin D status will be assessed by measuring serum 25-hydroxyvitamin D \[25(OH)D\] levels. Results will be recorded in ng/mL and used to evaluate vitamin D status in patients with stroke.
Time frame: First day of hospitalization for stroke patient, during an outpatient visit for non stroke control
Handgrip strength (kg)
Patients' muscle strength will be measured using a Baseline Digital Hand Dynamometer at 198 LB/90 kg for both the dominant and non-dominant extremities.
Time frame: First day of hospitalization for stroke patient, during an outpatient visit for non stroke control
Anterior thigh and anterior arm muscle thickness (mm)
Regional sarcopenia of the plegic and non-plegic extremities will also be assessed using the STAR formula with measurements of anterior thigh muscle thickness and anterior arm muscle thickness by ultrasound.
Time frame: First day of hospitalization for stroke patient, during an outpatient visit for non stroke control
Prealbumine
Prealbumin levels will be assessed by measuring serum prealbumin concentrations. Results will be recorded in mg/dL and used as a biochemical indicator of nutritional status in patients with stroke.
Time frame: First day of hospitalization for stroke patient, during an outpatient visit for non stroke control
Albumine
Serum albumin levels will be measured and recorded in g/dL as a biochemical parameter reflecting nutritional and inflammatory status in patients with stroke.
Time frame: First day of hospitalization for stroke patient, during an outpatient visit for non stroke control
Plan to share: No — The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion May 2026 → Dec 2026 and completion May 2026 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.